Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00781859 · ClinicalTrials.gov registry record · Phase 3
Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
A Phase 3 study, sponsored by ThromboGenics.
- Completed
- Registry status
- Phase 3
- Development phase
- 326
- Enrollment target
NCT00781859 is a Phase 3 study that has completed, run by ThromboGenics. The registered enrollment target is 326 participants.
The verdict
NCT00781859, a Phase 3 study, has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 326 participants
- Enrollment target
Study Summary
The objective of this trial is to evaluate the safety and efficacy of intravitreal microplasmin 125µg dose in subjects wiht focal vitreomacular adhesion.
Interventions
- DRUG Placebo
- DRUG 125 µg Ocriplasmin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00781859
The ClinicalTrials.gov registry entry for NCT00781859 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ThromboGenics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00781859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00781859 about?
NCT00781859 is a clinical study titled "Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.". The objective of this trial is to evaluate the safety and efficacy of intravitreal microplasmin 125µg dose in subjects wiht focal vitreomacular adhesion.
What is the current status of trial NCT00781859?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 326 participants. The study started on 2008-12. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00781859?
The interventions under investigation include: Placebo (DRUG), 125 µg Ocriplasmin (DRUG).
Who is sponsoring clinical trial NCT00781859?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.